Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer

PURPOSE: Cumulative anthracycline dose is one of the strongest predictors of heart failure (HF) after cancer treatment. However, the differential risk for cardiotoxicity between daunorubicin and doxorubicin has not been rigorously evaluated among survivors of childhood cancer. These risks, which are...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Feijen, Elizabeth A.M., Leisenring, Wendy M., Stratton, Kayla L., Ness, Kirsten K., van der Pal, Helena J.H., Caron, Huib N., Armstrong, Gregory T., Green, Daniel M., Hudson, Melissa M., Oeffinger, Kevin C., Robison, Leslie L., Stovall, Marilyn, Kremer, Leontien C.M., Chow, Eric J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2015
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4737860/
https://ncbi.nlm.nih.gov/pubmed/26304888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.61.5187
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi